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Abstract 
The CIRO Academy in Horn (the Netherlands) organized a two-day meeting to present and 
discuss the studies published in 2017 pertaining to key priority areas of respiratory and critical 
care medicine. This report provides a comprehensive review of the studies investigating all 
aspects of pulmonary rehabilitation and exercise training, physical activity and sedentary 
behaviour, acute and chronic respiratory failure as well as palliative respiratory care published in 
2017.  
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This report provides a comprehensive review of the studies investigating all aspects of 
pulmonary rehabilitation and exercise training, physical activity and sedentary behaviour, acute 
and chronic respiratory failure as well as palliative respiratory care published in 2017.  
 
Pulmonary Rehabilitation and Exercise Training 
In 2017, several studies considered novel aspects of patient assessment before and during 
pulmonary rehabilitation (PR) in chronic obstructive pulmonary disease (COPD) patients. The 
target training intensity in the PR exercise prescription is critically dependent on baseline 
exercise testing (1), which is associated with a learning effect (2). In a large national patient 
cohort from the UK, only 22.6% of patients had a practice walk test [six minute walking test 
(6MWT) or incremental shuttle walk test (ISWT)] at the start of PR (3). Moreover, in this cohort, 
practice walk tests were associated with an increase in PR enrolment and completion (1). The 
reasons for this are not clear, but merit further investigation. This study suggests that PR 
programs should be encouraged to perform practice walk tests whenever possible. Notably, a sit-
to-stand (STS) test was as a reliable and responsive measure of functional exercise capacity in 
COPD that correlated strongly with six minute walking test (6MWT) (4).  The STS could therefore 
potentially serve as an additional or alternate test from which to formulate the PR exercise 
prescription. STS testing also helps to predict long-term patient outcomes including mortality (5), 
hence its routine measurement in PR may have prognostic value for patients. Furthermore, 
responsiveness and minimal clinically important difference values for the COPD assessment test 
(CAT), clinical COPD questionnaire (CCQ) and hospital anxiety and depression score (HADS) have 
been published (6). Knowledge of these values will help clinicians to evaluate the efficacy of their 
PR programs regarding these outcomes.   
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Although pain (7), fatigue (8), and cognitive impairment (9) are common among COPD patients 
attending PR, these symptoms are commonly overlooked. Indeed, clinical features typically 
assessed in PR do not distinguish those COPD patients with and without cognitive impairment 
(9). Importantly, patients with cognitive impairment were still shown to benefit from PR (10). 
Cardiac abnormalities (11) and peripheral arterial disease (12) are also prevalent yet remain often 
undiagnosed among individuals who participate in PR. Although comorbidities do not adversely 
affect PR outcomes per se (13), screening for each of these comorbidities may be considered 
among PR participants, since under-diagnosis deprives patients of the opportunity to receive 
proper medical treatment and in turn poses risk of adverse health outcomes such as episodes of 
congestive heart failure, cardiac ischemia, claudication and/or limb ischemia. 
 
Likewise, patients who have mild to moderate severity acute exacerbations of COPD (AECOPD) 
during PR still achieve significant gains in 6MWT, although AECOPD requiring hospitalization are 
associated with a decline in 6MWT and higher PR dropout rates (14).  Furthermore, a cohort 
study from the UK showed an association between socioeconomic disadvantage and lower 
adherence to and completion of PR (15). Socioeconomic disadvantage was not, however, 
associated with lower gains in exercise performance or health status following PR (15). Notably, 
individuals with COPD who have a spouse or partner caregiver have an 11-fold greater odds of 
participation in PR than those lacking this social support (16). Importantly, home-based exercise 
interventions are both safe and beneficial, and may also be helpful for individuals who lack access 
to or are unable to participate in centre-based PR programs (17, 18).  
A multicentre RCT demonstrated benefits of an intensive post-PR maintenance exercise program 
on 6MWT and the body-mass index, airflow obstruction, dyspnoea, and exercise (BODE) scores 
up to 2 years post-PR, but without a significant benefit for quality of life (19).  Repeat PR 
programs were also effective, irrespective of the time period between programs (20), hence may 
6 
 
“This article has been accepted for publication in Thorax, 2019 following peer review, and the Version of Record can be accessed online at 
https://doi.org/10.1136/thoraxjnl-2018-212044.” 
“© Authors (or their employer(s)) 2019 Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and 
other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of 
the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/” 
be considered according to clinical need. Supporting previous studies, a nationwide Japanese 
retrospective observational cohort study reduced readmission risk with early PR delivered 
following hospitalization (21). 
Various forms of exercise training are beneficial in PR. Arm strength training leads to gains in 
upper extremity strength and endurance, with associated improvements in performance of 
activities of daily living (22). Whole body vibration training improves balance, muscle power 
output and exercise performance, and may be a particularly suitable training modality for 
individuals with impaired balance and low exercise capacity (23). Novel work, utilising  functional 
MRI imaging, tested whether neural responses to visual word cues were altered by participation 
in 6 weeks of outpatient PR among individuals with mild to moderate severity COPD (24). 
Changes in patients' ratings of breathlessness and anxiety in response to word cues for a range 
of activities after, as compared to before PR were associated with specific regional changes in 
brain activity. For example, changes in ratings of breathlessness during activities after 
PR correlated positively with metabolic activity in the insula and anterior cingulate cortex. 
Baseline activity in selected brain regions also correlated with improvements in breathlessness 
and anxiety after PR. This work suggests that aspects of neural signalling can be altered by 
participation in PR, perhaps by changes in learned associations between environmental stimuli 
and brain perception. Future use of functional MRI imaging to better understand individuals' 
neural responses to exercise training and other components of PR may help to develop 
strategies to target specific aspects of learning that could ultimately optimize individualization 
and efficacy of PR. 
 
Physical activity and sedentary behaviour  
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The degree of airflow limitation is only moderately related to daily physical activity (PA) levels in 
patients with COPD (25), stressing the importance of searching for extra-pulmonary barriers and 
enablers that may affect PA (26). Proximity of residence to green or open spaces and 
neighbourhood deprivation are not determinants of PA, but dog walking and grand parenting are 
(27). Consequently, encouraging patients to walk the dog and/or take care of grandchildren 
seems to be a feasible way to boost the PA level of these patients. Moreover, spouses may play 
an important role in changing PA behaviour in patients with COPD, as patients with a physically 
active spouse were physically more active themselves (28).  
Sedentary behaviour (>8:30 hours/day spent in activities of intensity <1.5 metabolic equivalents) 
increases the 5-year mortality risk in patients with COPD (29). So, an in-depth assessment PA 
behaviour (sedentarism and the PA) seems of clinical relevance. Furthermore, impaired sleep 
quality is closely related to less PA (30). Therefore, PA-enhancing interventions need to take 
sleep quality into consideration .  
 Changes in PA following different exercise-based interventions showed contrasting results.  The 
amount and intensity of PA increased by using a 12-week semi-automated tele-coaching 
intervention including a step counter and an app installed on a smartphone (31). In contrast, 
pedometer-directed step targets were unable to enhance the effects of PR on PA (32). Also after 
a comprehensive PR program, different response profiles for changes in PA were found (33). 
Poor responders are likely to be the focus of attention in future PA-enhancing interventions, 
provided the patient has enough functional capacity in order to reduce sedentary behaviour and 
increase physical activity levels. Hence, this recent body of evidence justifies the clinical relevance 
of features such as the value of objectively assessing the degree of sedentarism and the increase 
in PA derived from factors around the patient (e.g., spouse, grandchildren and pets). Attention 
should also be drawn to the profile of response to PR (i.e., identifying poor PA responders), as 
well as to the components and timing of PA interventions. 
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Exercise training combined with oxygen supplementation or non-invasive ventilation 
The Long-Term Oxygen Treatment Trial (34) showed no effect of LTOT on first hospitalization 
and death over 6 years in 738 COPD patients with moderate hypoxia. However, the limitations of 
this trial suggest that further studies are needed before definitive conclusions regarding the 
benefits of LTOT for individuals with COPD and moderate hypoxia can be drawn. Short-term 
effects of oxygen supplementation on exercise performance appear more conclusive.  Indeed,  
oxygen supplementation (10 l/min) in 29 non-hypoxemic COPD patients during exercise doubled 
peak work rates compared to room air (35). This, however, is not a typical real-life approach.  
An oxygen supplementation of 2 l/min during 6-minute walk test improved exercise performance 
and oxygen saturation, and reduced dyspnoea and the number of unintended breaks compared 
to room air in COPD patients with hypoxia at rest or during exercise (36). Regarding patients with 
ILD, one small study (n=20) has shown the non-inferiority of two portable concentrators 
compared to O2-cylinders (37). Interestingly, an interview based study including 26 Australian 
respiratory physicians presumed a higher probability of prescribing LTOT in ILD compared to 
COPD patients (38).  
Using NIV to enhance exercise performance in patients with respiratory failure has a reasonable 
physiological rationale but it has not been shown to improve walking distance (39). The authors, 
however, combined  the results of patients with COPD and kyphoscoliosis, which made it difficult 
to draw a clear conclusion. Indeed, NIV is not expected to be beneficial in patients with 
kyphoscoliosis. During a specialized inpatient PR study, 296 of 1044 patients awaiting lung 
transplantation received nocturnal NIV due to hypercapnia (40). The increase in 6MWD after PR 
in the NIV group was higher, albeit by only 11 meters.  LTOT and NIV are potentially valuable 
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therapeutic options, in particular to support COPD patients with severe lung hyperinflation and 
exercise-induced oxygen desaturation (41) in the context of exercise training as part of a 
comprehensive PR program. Further well-designed studies are needed to prove these concepts 
and to enable physicians to identify ideal candidates for these therapeutic options more easily. 
 
Nutritional modulation with(out) exercise training 
The latest Cochrane meta-analysis (42) reported moderate quality evidence of nutritional 
supplementation on body weight, body composition, exercise performance and quality of life in 
malnourished COPD patients. This conclusion was substantiated by a single blinded RCT 
conducted in India (43). Unintended weight loss is more frequent in severe disease but in a UK 
COPD population, Collins and colleagues (44) additionally highlighted the importance of 
deprivation on malnutrition risk. Most studies to date focused on nutritional intervention in 
clinical stable disease, but an Australian study showed hospitalization as ‘window of opportunity’ 
to start up nutritional modulation, as malnourished COPD patients experienced significantly 
longer hospital stays at double the cost (45). 
A shift in nutritional approaches, from protein-calorie supplementation to maintain body weight 
and muscle mass, to treating nutrient deficiencies and optimizing plasma nutrient status, to 
modulate physical function and cardiovascular risk is occurring (46-48). Low muscle mass and 
abdominal obesity may coexist in normal weight COPD patients with elevated cardiovascular risk 
profile (49). Next to low muscle mass, a high prevalence of deficiencies in vitamin D, vitamin B12 
and iron in hospitalized COPD are reported (46). Calder and colleagues (47) investigated 3 
months of multimodal nutritional intervention including high quality protein, vitamin D and n-3 
fatty acids versus an iso-caloric control, and showed positive effects on blood pressure, blood 
lipids and on exercise-induced fatigue. A Dutch trial (48) investigated the efficacy of a similar 
10 
 
“This article has been accepted for publication in Thorax, 2019 following peer review, and the Version of Record can be accessed online at 
https://doi.org/10.1136/thoraxjnl-2018-212044.” 
“© Authors (or their employer(s)) 2019 Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and 
other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of 
the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/” 
multimodal nutritional intervention as adjunct to 4 months high-intensity exercise training. 
Muscle mass and physical performance improved in both groups, but the intervention group 
showed additional effects on nutritional status and physical activity compared to placebo. These 
data suggest that targeted multimodal nutritional modulation combined with exercise training 
has an beneficial effect in patients with COPD. Nevertheless, nitrate, which has been proposed as 
pharmaco-nutrient to modulate extra-pulmonary pathology via multiple pathways, did not 
influence cycling efficiency, physical performance and cardiac biomarkers in a cross-over, proof 
of concept RCT (50).  
 
Early rehabilitation during critical illness 
Acute skeletal muscle wasting occurs early and rapidly during critical illness (51).  The clinical 
priority is to reduce acute muscle wasting as this is a major driver of long-term disability (52). This 
has provided the rationale for clinical trials investigating early mobilization and exercise therapy 
within the ICU with the primary goal of enhancing functional outcome, health-related quality of 
life and reducing healthcare utilization (53-57).  
 
The outcome from these trials has been inconsistent with three trials demonstrating no benefit 
from early ICU mobilization (53-55) and two trials demonstrating benefit from early ICU 
mobilization (56, 57). We must consider the “PICO“ approach (target population, intervention 
delivered, control comparator and primary outcome) to understand the clinical effectiveness 
differences between the trials. The target populations of the medical ICU trials (53-55, 57) 
differed with ages ranging from 53 to 62 years with the trials recruiting patients with acute lung 
injury/acute respiratory distress syndrome and varying frequencies of co-morbidities (Table 1). 
The mean length of ICU stay was 6 to 16 days across the trials further highlighting the different 
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target populations in terms of recovery trajectory. These factors are wholly relevant as recent 
data has demonstrated that age, ICU length of stay and co-morbidity burden effect the outcome 
post critical illness (58).   
Table 1: Patient Characteristics in the medical early mobilisation trials  
 Schweikert et al 
(57) 
Moss et al (55) Morris et al (54) Wright et al (53) 
Mean Age 
(years) 
56 53 56 62 
Matching 
Gender 
No Yes Yes No 
Primary 
Diagnosis 
AlI 
Medical 
ARDS 
Medical 
ARF 
Medical 
Mixed 
Medical/Surgical 
Co-
Morbidities 
Reported 
Diabetes Diabetes, 
cirrhosis, 
cancer, renal 
failure, HIV, 
organ 
transplantation 
Not reported Pre-Morbid  
Katz Index 
ICU LOS  
(Days) 
6.9 15.5 7.8 5.5 
 
In regard to the intervention delivered, we must also consider the dose, intensity and timing of an 
intervention.  The trial that demonstrated a benefit in functional outcome delivered 19 minutes per 
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day of exercise therapy dose prior to cessation of mechanical ventilation compared to the control 
group (57), whereas the other trials (53-55) delivered only 10 minutes per day.  The within ICU 
sessions in the Moss et al study (55) was 31 minutes per day in the treatment group vs. 21 minutes 
per day in the control group, a similar difference to the Wright et al study (53) which demonstrated 
23 minutes per day vs. 13 minutes per day.  In addition, the exercise therapy was delivered 1.5 days 
post initiation of mechanical ventilation (57) in this trial, whilst the other trials initiated exercise 
therapy between 4-8 days.  Furthermore, the importance of intensity of the treatment is 
highlighted by the difference between the study by Morris et al (54), which delivered treatment 
for only approximately 50% of the intervention days, compared with the Schweickert et al (57) 
study that provided physical and occupational therapy for 90% of the mechanical ventilator days.     
Establishing the barriers and enablers to early mobilization will promote better application of 
exercise therapy in critically ill patients (59). Early mobilisation needs to be targeted at the 
appropriate ICU population, with current data supporting application very early in the course of 
critical illness. The severity of the acute illness determines the degree of muscle wasting (51), with 
age, ICU length of stay, systemic inflammation and chronic health prior to critical illness 
determining the trajectory of recovery (58). In addition, decreased mitochondrial biogenesis and 
dysregulated lipid oxidation contribute to a compromised skeletal muscle bioenergetic status with 
intramuscular inflammation associated with impaired anabolic recovery (60) and development of 
ICU acquired weakness(61).  Future clinical work will need to focus on these key areas with the 
establishment of the appropriate timing, dose and frequency of both phramcological and non-
pharmacological treatments.  
 
Home-management of chronic respiratory failure 
13 
 
“This article has been accepted for publication in Thorax, 2019 following peer review, and the Version of Record can be accessed online at 
https://doi.org/10.1136/thoraxjnl-2018-212044.” 
“© Authors (or their employer(s)) 2019 Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and 
other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of 
the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/” 
NIV can be used for long-term treatment of chronic respiratory failure in the home environment. 
In patients with obesity hypoventilation syndrome, recent data suggests that NIV and continuous 
positive airway pressure results in a similar improvement in arterial blood gas measurement and 
health-related quality of life (62). A meta-analysis assessing the efficacy of long-term NIV in COPD 
patients has shown that the arterial partial pressure of carbon dioxide (PaCO2) can be decreased 
with NIV with mortality improved with a significant reduction in PaCO2 by NIV (63). This is 
supported by recent studies that have demonstrated that effective NIV, with the aim of 
significantly reducing elevated PaCO2, is well tolerated and associated with improvements in 
quality of life (64) and long-term survival (65). Furthermore, evidence supports the use of home 
oxygen therapy and home mechanical ventilation (HOT-HMV) in COPD patients following acute 
respiratory failure and persistent hypercapnia e.g. COPD patients with acute on chronic 
respiratory failure (66). In the HOT-HMV clinical trial, the addition of home NIV to home oxygen 
therapy prolonged the time to readmission or death within 12 months (66).  
 
Palliative respiratory care in COPD 
Timely integration of palliative COPD care with disease-oriented treatment can improve patient 
as well as informal caregiver outcomes (67). However, the unpredictable disease trajectory in 
COPD is a challenge for timely provision of end-of-life care. Indeed, patients with COPD were less 
likely to die at home than patients with lung cancer (68). Prognostic variables and multivariate 
scores contributing to an accurate risk assessment for death within 12 months are mostly lacking 
(69). Identifying patients in need for palliative care thus remains a challenge (70). The initiation of 
palliative care, therefore, should be based on complexity of symptoms and unmet needs instead 
of estimation of prognosis (67).  
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Two meta-analyses addressed opioid use for breathlessness, a major problem for patients with 
advanced disease. Ekström and colleagues (71) confirmed that short-term use of opioids are 
associated with statistically significant as well as clinically relevant reductions in breathlessness 
severity. Verberkt and colleagues (72) explored respiratory adverse effects of opioids, a 
frequently mentioned physician-endorsed barrier towards opioid prescription. After exploring 67 
studies no evidence was found of significant or clinically relevant respiratory adverse effects of 
short-term use of opioids for chronic breathlessness. 
In 2017 the European Association for Palliative Care published a consensus-based definition as 
well as recommendations for advance care planning (ACP) (73). Jabbarian and colleagues (74) 
performed a systematic review of preferences and practices of ACP in chronic respiratory 
diseases. They showed that a majority of patients are interested in engaging in ACP, but despite 
this, ACP is rarely done. Moreover, ACP is a continuous process between patients and physicians, 
in which preferences for specific situations are discussed and that needs to be regularly re-
evaluated to deliver high-quality end-of-life care (75). Although clinicians acknowledge the 
importance of ACP, they are hesitant to initiate ACP. A nurse-led ACP-intervention can increase 
ACP discussions and completion of advance directives and appointment of a substitute medical 
decision-maker (76); and can facilitate patient-physician communication about end-of-life care 
without causing psychological distress in both patients and their loved ones (77). Palliative care 
can also reduce use of healthcare services (78). When acute respiratory failure ensues in 
terminally ill patients, NIV may be applied, as recently suggested by the ERS/ATS guidelines, with 
the sole aim of palliating dyspnoea, and eventually give more time to say goodbye to the loved 
ones (79). 
So, these recent studies show that effective palliative care interventions are available for patients 
with COPD, for example for symptom management, but also interventions addressing advance 
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care planning needs. Nevertheless, identifying patients in need for palliative care remains a 
challenge and this should be a focus for future research. 
 
 
Palliative respiratory care in interstitial lung diseases 
Palliative care needs, access to palliative care and symptom management in patients with 
interstitial lung diseases are presented in a summary paper (80).  
A qualitative study of current patients, current and past caregivers confirmed wide-ranging needs 
and the challenges of advance care planning. Caregivers of decedents reported symptoms and 
frustration with education provided more frequently indicating re-framing of experience after 
the patient’s death (81). An observational study of patients and caregivers (Netherlands, 
Germany) attending information/education days including end-of-life care topics showed most 
wished to know everything about their condition, and that the information had improved 
feelings of security, belying clinicians’ concerns of taking away hope (82). However, study group 
participants are self-selected information-seekers.  
In practice, access to neither general (respiratory and primary care teams) nor specialist 
(palliative care teams) palliative care is routine (https://www.brit-thoracic.org.uk/document-
library/audit-and-quality-improvement/lung-disease-registry/bts-ild-registry-programme-annual-
report-201415/). Recent advances include development and validation of the NICE endorsed 
Needs Assessment Tool for Interstitial Lung Disease (NAT:ILD; http://www.hyms.ac.uk/go/nat-pd-
ild) to help respiratory clinicians identify palliative needs of patients and caregivers, and triage 
referral to specialist palliative care (83, 84). Implementation in practice requires service 
reconfiguration to allow holistic assessment, training in communication skills and symptom 
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management and support from palliative care services (85). Symptoms are burdensome in ILD. 
Preliminary data show improvement in subjective and objective cough by pirfenidone (86). 
Breathlessness is of major importance; an Australian IPF registry study showed that 
breathlessness predicted quality of life explaining over 70% of the variation in the model (87). A 
primary care study showed increased consultations due to breathlessness by people, some up to 
five years prior to IPF diagnosis (88). The importance of breathlessness management in addition 
to ILD-directed treatment is emphasized in a recent consideration of chronic breathlessness as a 
new clinical syndrome, defined as disabling breathlessness, persistent despite optimized disease-
modifying treatment (89).  Consistent with this, a systematic review and qualitative synthesis of 
101 papers proposed a new concept of “breathing space” – maximum living with chronic 
breathlessness - encompassing patients’ coping, help-seeking, and clinicians’ responsiveness to 
breathlessness as a distinct entity (90).     
ILDs are therefore identified as a group of diseases which carry a large symptom burden, 
especially breathlessness which has particularly wide-reaching detrimental effects on quality of 
life. Holistic assessment with attention to symptom management, information need and planning 
for the future are key to excellent care but is rarely done systematically. A validated assessment 
tool is now available but care is needed with implementation with consideration to service 
reconfiguration to allow sufficient time, resources and training. 
 
Future directions 
As outlined above, the fields of PR, physical activity, home management of respiratory failure, 
and palliative respiratory care have made substantial progress over the last year. Innovative 
methods to assess the broad needs of individual patients with chronic respiratory diseases have 
been proposed, novel interventions and/or indications for existing therapies have been 
17 
 
“This article has been accepted for publication in Thorax, 2019 following peer review, and the Version of Record can be accessed online at 
https://doi.org/10.1136/thoraxjnl-2018-212044.” 
“© Authors (or their employer(s)) 2019 Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and 
other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of 
the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/” 
evaluated, and new models for providing healthcare have been confirmed. However, several 
gaps in our knowledge remain and need to be addressed in future research. While PR assessment 
and interventions are aimed to provide a comprehensive and individualized treatment (91) and 
recent meta-analysis and guidelines confirmed the overall benefits of PR (1, 92, 93), not all 
patients improve as a result of this intervention (94, 95).  Similarly, systematic reviews of 
palliative care interventions suggest benefit, but work is needed to identify the best intervention 
for individual patients (96).  Research is needed to help understand the organizational aspects, 
patient characteristics and interventional factors related to treatment benefit, individualizing 
treatments to address specific patient needs, and improve cost-effectiveness of interventions. In 
addition, development of multidimensional and individualized outcome assessment is required to 
reflect the personalized and comprehensive nature of these treatments (95). Also, the 
effectiveness and the best approaches to integrate PR with palliative care for patients with 
advanced and complex chronic respiratory diseases need to be investigated. Furthermore, we 
need to study the effects of interventions combining traditional PR and palliative care with 
innovative medical treatments for patients with different but advanced chronic respiratory 
diseases. Such interventions may include the addition of high-flow oxygen therapy for patients 
with severe exercise-induced desaturation (97), non-invasive ventilation for patients with 
pronounced hyperinflation and/or hypercapnia (98), endobronchial interventions for patients 
with severe emphysema (99, 100), and biologicals for patients with severe obstructive lung 
diseases (101). Finally, we should aim for (combined) therapies that are supportive for the patient 
to take the responsibility as specialists of their own lives: patients must become co-creators of 
value care (102). 
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